| 2025-01-13 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2025-01-13 |
6-K |
GSK ENTERS AGREEMENT TO ACQUIRE IDRX, INC. |
View Document |
| 2025-01-10 |
6-K |
SHINGRIX FULLY LIQUID ACCEPTED FOR US FDA REVIEW |
View Document |
| 2025-01-07 |
6-K |
GSK ADC GETS FDA BREAKTHROUGH THERAPY DESIGNATION |
View Document |
| 2025-01-03 |
6-K |
GSK'S NUCALA APPROVED IN CHINA FOR USE IN CRSWNP |
View Document |
| 2025-01-02 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2024-12-23 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-12-20 |
6-K |
BLOCK LISTING APPLICATION |
View Document |
| 2024-12-20 |
6-K |
HEADLINE RESULTS FROM PHASE III FIRST TRIAL |
View Document |
| 2024-12-16 |
6-K |
JEMPERLI RECEIVES US FDA BREAKTHROUGH DESIGNATION |
View Document |
| 2024-12-16 |
6-K |
EMA GRANTS PRIME DESIGNATION FOR GSK 227 |
View Document |
| 2024-12-16 |
6-K |
JEMPERLI RECEIVES POSITIVE CHMP OPINION |
View Document |
| 2024-12-12 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-12-09 |
6-K |
OVERALL SURVIVAL DATA PRESENTED FOR BLENREP |
View Document |
| 2024-12-09 |
6-K |
BLENREP COMBINATION CHINA FILING ACCEPTANCE |
View Document |
| 2024-12-09 |
6-K |
NUCALA COPD SUBMISSION ACCEPTED BY US FDA |
View Document |
| 2024-12-05 |
6-K |
ZHIFEI CHINA COLLABORATION REVISED AND EXTENDED |
View Document |
| 2024-12-02 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-12-02 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2024-11-27 |
6-K |
GSK LIQUID MENINGITIS VACCINE AUTHORISED IN EU |
View Document |
| 2024-11-25 |
6-K |
BLENREP COMBINATIONS ACCEPTED FOR US FDA REVIEW |
View Document |
| 2024-11-22 |
6-K |
JAPAN APPROVES FIRST RSV VACCINE FOR ADULTS 50-59 |
View Document |
| 2024-11-19 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-11-19 |
6-K |
GLISTEN TRIAL OF LINERIXIBAT MEETS ENDPOINT |
View Document |
| 2024-11-15 |
SC 13D/A |
AMENDMENT TO THE SCHEDULE 13D |
View Document |
| 2024-11-14 |
6-K |
GSK ANNOUNCES OVERALL SURVIVAL RESULTS FOR BLENREP |
View Document |
| 2024-11-13 |
6-K |
BLOCK LISTING INTERIM REVIEW |
View Document |
| 2024-11-12 |
SC 13G/A |
AMENDMENT TO FORM SC 13G |
View Document |
| 2024-11-12 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-11-12 |
6-K |
GSK PUBLISHES PROVISIONAL 2025 DIVIDEND DATES |
View Document |
| 2024-11-01 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2024-10-30 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-10-30 |
6-K |
3RD QUARTER RESULTS |
View Document |
| 2024-10-24 |
6-K |
NEW POSITIVE AREXVY DATA IN YOUNGER ADULTS AT RISK |
View Document |
| 2024-10-17 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-10-16 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-10-16 |
6-K |
FDA ACCEPTS NEW DRUG APPLICATION FOR GEPOTIDACIN |
View Document |
| 2024-10-15 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-10-15 |
6-K |
POSITIVE RESULTS OF ANCHOR TRIALS OF DEPEMOKIMAB |
View Document |
| 2024-10-11 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-10-10 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-10-09 |
6-K |
ZANTAC (RANITIDINE) LITIGATION SETTLEMENTS |
View Document |
| 2024-10-08 |
6-K |
POSITIVE EFFICACY DATA OF AREXVY OVER 3 SEASONS |
View Document |
| 2024-10-01 |
4 |
WVE - CHANGE IN BENEFICIAL OWNERSHIP |
View Document |
| 2024-10-01 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2024-09-24 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-09-24 |
6-K |
POSITIVE EU OPINION FOR GSK LIQUID MENVEO VACCINE |
View Document |
| 2024-09-18 |
6-K |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
View Document |
| 2024-09-17 |
6-K |
JAPAN FILING ACCEPTANCE: BLENREP MULTIPLE MYELOMA |
View Document |
| 2024-09-13 |
6-K |
CHINA BREAKTHROUGH THERAPY DESIGNATION FOR BLENREP |
View Document |
| 2024-09-12 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-09-12 |
6-K |
POSITIVE MRNA FLU VACCINE PHASE II HEADLINE DATA |
View Document |
| 2024-09-11 |
6-K |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
View Document |
| 2024-09-11 |
6-K |
CHANGE OF REGISTERED OFFICE |
View Document |
| 2024-09-11 |
6-K |
UPDATE ON PHASE I/II THERAPEUTIC HSV VACCINE TRIAL |
View Document |
| 2024-09-09 |
6-K |
DEPEMOKIMAB LATE-BREAKING DATA PRESENTED AT ERS |
View Document |
| 2024-09-06 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-09-06 |
6-K |
POSITIVE PHASE III RESULTS FOR NUCALA IN COPD |
View Document |
| 2024-09-03 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2024-08-29 |
6-K |
EMA APPROVAL ON AREXVY FOR 50-59 AT RISK |
View Document |
| 2024-08-28 |
6-K |
NUCALA APPROVED IN JAPAN FOR USE IN CRSWNP |
View Document |
| 2024-08-28 |
6-K |
SENKU DESIGNATION FOR BEPIROVIRSEN IN JAPAN |
View Document |
| 2024-08-28 |
6-K |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
View Document |
| 2024-08-21 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-08-20 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-08-20 |
6-K |
B7-H3 ADC US FDA BREAKTHROUGH THERAPY DESIGNATION |
View Document |
| 2024-08-16 |
6-K |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
View Document |
| 2024-08-12 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-08-06 |
6-K |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
View Document |
| 2024-08-02 |
6-K |
FDA EXPANDS JEMPERLI APPROVAL |
View Document |
| 2024-08-01 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2024-07-31 |
6-K |
2ND QUARTER RESULTS |
View Document |
| 2024-07-29 |
6-K |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
View Document |
| 2024-07-29 |
6-K |
CHMP POSITIVE OPINION ON AREXVY FOR 50-59 AT RISK |
View Document |
| 2024-07-19 |
6-K |
BLENREP EMA FILING ACCEPTANCE |
View Document |
| 2024-07-18 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-07-16 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-07-15 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-07-12 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-07-03 |
6-K |
GSK AND CUREVAC COLLABORATION RESTRUCTURED |
View Document |
| 2024-07-01 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2024-06-28 |
6-K |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
View Document |
| 2024-06-24 |
6-K |
EMA VALIDATES JEMPERLI MARKETING AUTHORISATION |
View Document |
| 2024-06-24 |
6-K |
OMJJARA APPROVED IN JAPAN FOR MYELOFIBROSIS |
View Document |
| 2024-06-21 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-06-18 |
11-K |
ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE |
View Document |
| 2024-06-18 |
11-K |
ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE |
View Document |
| 2024-06-12 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-06-11 |
6-K |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
View Document |
| 2024-06-10 |
6-K |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
View Document |
| 2024-06-10 |
6-K |
FDA APPROVES AREXVY FOR ADULTS 50-59 AT RISK |
View Document |
| 2024-06-03 |
25-NSE |
|
View Document |
| 2024-06-03 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2024-06-03 |
6-K |
UNPRECEDENTED RESULTS IN JEMPERLI TRIAL CONTINUE |
View Document |
| 2024-06-03 |
6-K |
ASCO POSITIVE BLENREP DREAMM-8 TRIAL RESULTS |
View Document |
| 2024-06-03 |
6-K |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
View Document |
| 2024-05-31 |
SD |
SPECIALIZED DISCLOSURE REPORT |
View Document |
| 2024-05-24 |
6-K |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
View Document |
| 2024-05-21 |
6-K |
POSITIVE PHASE III ASTHMA RESULTS FOR DEPEMOKIMAB |
View Document |
| 2024-05-20 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
